Oppenheimer Turns Bullish on Relay Therapeutics Ahead of Key Data
Oppenheimer upgrades Relay Therapeutics to Outperform, citing potential upside from competitor trial risks and upcoming VIKTORIA-1 results.
Already have an account? Sign in.